Diapositive 1

103 / 1851

rogram
ame
Lead
organization
Design Histology Indication
# Expected
to accrue
Primary
outcome
measure(s)
v identifier
IGNATURE Novartis NR
PI3K-activated
solid tumors
and/or
hematologic
malignancies
Metastatic 145 CBR NCT01833169
BRAFV600-
mutated solid
tumors and/or
hematologic
malignancies
Metastatic 12 CBR NCT01981187
PTCH1 or SMO
mutated
Metastatic 10 CBR NCT02002689
RAS/RAF/MEK
activated
Metastatic 110 CBR NCT01885195
CDK4/6 pathway
activated
Metastatic 90 CBR NCT02187783
FGFR mutated Metastatic 70 CBR NCT02160041
Basket trials matching patients to therapies
based on molecular profiles